Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIPRO: Chiauranib plus Paclitaxel in Ovarian Cancer
NCT04921527Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Chiauranib + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoints: Progression-Free Survival at 1 year and Overall Survival at 2 years. Started Dec 2021; status: recruiting.
02
Drugs
chiauranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04921527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921527.